A new convenient synthetic method and preliminary pharmacological characterization of triazinediones as prokineticin receptor antagonists
摘要:
A new efficient synthetic method to obtain prokineticin receptor antagonists based on the triazinedione scaffold is described. In this procedure the overall yield improves from 13% to about 54%, essentially for two factors: 1) N-(chlorocarbonyl) isocyanate is no more used, it represents the yield limiting step with an average yield not exceeding 30%. 2) The Mitsunobu reaction is not involved in the new synthetic scheme avoiding the use of time and solvent consuming column chromatography. All synthesized triazinediones were preliminary pharmacologically screened in vivo for their ability to reduce the Bv8-induced thermal hyperalgesia. In this assay all compounds displayed EC50 values in the picomolar-subpicomolar range, some triazinediones containing a 4-halogen substituted benzyl group in position 5 showed the best activity. The analogues containing a 4-fluorine atom (PC-7) and a 4-bromobenzyl group (PC-25) resulted 10 times more potent than the reference PC-1 that bears a 4-ethylbenzyl group. While the 4-trifluoromethylbenzyl substituted analog (PC-27) was 100 times more potent as compared to PC1. (C) 2014 Elsevier Masson SAS. All rights reserved.
A series of 3-(arylalkyl)-2,4,5-trioxoimidazolidine-1-acids (1) was prepared and tested for aldose reductase (AR) and aldehyde reductase (ALR) inhibitory activities. These compounds showed strong inhibitory activity against AR without significant inhibitory activity for ALR. The ratio of IC50(ALR)/IC50(AR) was > 1000 in some compouds. On the basis of pharmacological tests such as the recovery of reduced motor nerve conduction velocity and toxicological profile, 3-(3-nitrobenzyl)-2,4,5-trioxoimidazolidine-1-acid (NZ-314) was selected as the candidate for clinical development.
[EN] NOVEL CATHEPSIN C INHIBITORS AND THEIR USE<br/>[FR] NOUVEAUX INHIBITEURS DE LA CATHEPSINE C ET LEUR UTILISATION
申请人:GLAXO GROUP LTD
公开号:WO2009026197A1
公开(公告)日:2009-02-26
The invention is directed to compounds according to Formula (I) wherein R1, R2a, R2b, R2c, R3, and n are defined below, and to pharmaceutically-acceptable salts thereof. They are cathepsin C inhibitors and can be used in the treatment of diseases mediated by the cathepsin C enzyme, such as COPD.
Ammonium Chloride‐Promoted Rapid Synthesis of Monosubstituted Ureas under Microwave Irradiation
作者:Chunling Blue Lan、Karine Auclair
DOI:10.1002/ejoc.202101059
日期:2021.10.7
Ammonium chloride promotes the selective formation of monosubstituted ureas undermicrowaveirradiation. Most nucleophiles, acid-labile functionalities, and protecting groups are well tolerated in this reaction. By avoiding transition metals and mineral acids, this methodology offers a more sustainable alternative for the synthesis of monosubstituted ureas and their analogs.
[EN] NOVEL COMPOUNDS THAT ARE ERK INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS QUI SONT DES INHIBITEURS D'ERK
申请人:MERCK SHARP & DOHME
公开号:WO2013063214A1
公开(公告)日:2013-05-02
Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).
The Direct Decarboxylative <i>N</i>-Alkylation of Azoles, Sulfonamides, Ureas, and Carbamates with Carboxylic Acids via Photoredox Catalysis
作者:Peijun Li、Jason R. Zbieg、Jack A. Terrett
DOI:10.1021/acs.orglett.1c03761
日期:2021.12.17
describe a method for the direct decarboxylative C–Ncoupling of carboxylic acids with a range of nitrogen nucleophiles. This platform employs visible-light-mediated photoredox catalysis and an iodine(III) reagent to generatecarbocation intermediates directly from aliphatic carboxylic acids via a radical-polar crossover mechanism. A variety of C–N bond-containing products are constructed from a diverse